{
    "nct_id": "NCT04340258",
    "official_title": "Phase 1b/II Trial Combining PD1 Inhibition (Pembrolizumab) and Cesium 131 Brachytherapy With Salvage Surgery to Enhance Immunogenicity and Improve Local Control in Head and Neck Cancer",
    "inclusion_criteria": "* locally recurrent HNSCC and be eligible for salvage surgery\n* If patient received radiation therapy in the past, they should have recovered from the acute toxicity to <grade 1\n* tumor needs to be deemed resectable\nHealthy volunteers allowed\nMust have minimum age of 19 Years\nMust have maximum age of 90 Years",
    "exclusion_criteria": "* Exposed carotid artery preoperatively requiring sacrifice or bypass intra-operatively\n* Patients with active pharyngo-cutaneous\n* Patients with more than one site of distant metastatic disease\n* Prior immune-based anticancer therapy within last six months",
    "miscellaneous_criteria": ""
}